| Autor: |
Gedye, Craig, Quirk, Juliet, Browning, Judy, Svobodová, Suzanne, John, Thomas, Sluka, Pavel, Dunbar, P. Rod, Corbeil, Denis, Cebon, Jonathan, Davis, Ian D. |
| Předmět: |
|
| Zdroj: |
Cancer Immunology, Immunotherapy; Oct2009, Vol. 58 Issue 10, p1635-1646, 12p, 1 Color Photograph, 1 Chart, 4 Graphs |
| Abstrakt: |
“Cancer stem cells” that resist conventional treatments may be a cause of therapeutic failure in melanoma. We report a subpopulation of clonogenic melanoma cells that are characterized by high prominin-1/CD133 expression in melanoma and melanoma cell lines. These cells have enhanced clonogenicity and self-renewal in vitro, and serve as a limited in vitro model for melanoma stem cells. In some cases clonogenic CD133+ melanoma cells show increased expression of some cancer/testis (CT) antigens. The expression of NY-ESO-1 in an HLA-A2 expressing cell line allowed CD133+ clonogenic melanoma cells to be targeted for killing in vitro by NY-ESO-1-specific CD8+ T-lymphocytes. Our in vitro findings raise the hypothesis that if melanoma stem cells express CT antigens in vivo that immune targeting of these antigens may be a viable clinical strategy for the adjuvant treatment of melanoma. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink